Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: Results from a phase 2 nonrandomized expansion cohort

European Urology

Volumn 67, Issue 2, 2015, Pages 310-318

  Basch, Ethan ^a   Autio, Karen A ^b,c   Smith, Matthew R ^d   Bennett, Antonia V ^a   Weitzman, Aaron L ^e   Scheffold, Christian ^e   Sweeney, Christopher ^f   Rathkopf, Dana E ^b   Smith, David C ^g   George, Daniel J ^h   Higano, Celestia S ⁱ   Harzstark, Andrea L ^j   Sartor, A Oliver ^k   Gordon, Michael S ^l   Vogelzang, Nicholas J ^m   De Bono, Johann S ⁿ   Haas, Naomi B ^o   Corn, Paul G ^p   Schimmoller, Frauke ^e   Scher, Howard I ^b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e EXELIXIS INC   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Pinnacle Oncology Hematology   (United States)

^m Medical Oncology Comprehensive Cancer Centers of Nevada   (United States)

ⁿ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

^p UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

mCRPC; Pain control; Patient reported outcomes; Phase 2 trial; Quality of life; Tyrosine kinase inhibitor

Indexed keywords

ABIRATERONE; CABAZITAXEL; CABOZANTINIB; DOCETAXEL; ENZALUTAMIDE; NARCOTIC AGENT; RADIOISOTOPE; ANILIDE; ANTINEOPLASTIC AGENT; NARCOTIC ANALGESIC AGENT; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; AGED; ANALGESIA; ARTICLE; BONE METASTASIS; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SCREENING; DRUG USE; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SELF REPORT; SLEEP DISORDER; SLEEP QUALITY; TREATMENT RESPONSE; CLINICAL TRIAL; COMPLICATION; GREAT BRITAIN; MIDDLE AGED; MULTICENTER STUDY; PAIN; PAIN MEASUREMENT; PALLIATIVE THERAPY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; ANALGESICS, OPIOID; ANILIDES; ANTINEOPLASTIC AGENTS; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; PYRIDINES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84920723172     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.02.013     Document Type: Article

References (34)

1. A.J. Armstrong, E.S. Garrett-Mayer, Y.C. Yang, R. de Wit, I.F. Tannock, and M. Eisenberger A contemporary prognostic monogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis Clin Cancer Res 13 2007 6396 6403
2. K.A. Autio, A.V. Bennett, and X. Jia Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure J Oncol Pract 9 2013 223 229
3. D.T. Aftab, and D.M. McDonald MET and VEGF: synergistic targets in castration-resistant prostate cancer Clin Transl Oncol 13 2011 703 709
4. B.S. Knudsen, G.A. Gmyrek, and J. Inra High expression of the Met receptor in prostate cancer metastasis to bone Urology 60 2002 1113 1117
5. F.M. Yakes, J. Chen, and J. Tan Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol Cancer Ther 10 2011 2298 2308
6. R. Kurzrock, S.I. Sherman, and D.W. Ball Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer J Clin Oncol 29 2011 2660 2666
7. D.C. Smith, M.R. Smith, and C. Sweeney Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial J Clin Oncol 31 2013 412 419
8. De Bono JS, Smith MR, Rathkopf D, et al. Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (mCRPC): results of a phase 2 non-randomized expansion cohort (NRE). Presented at: European Society for Medical Oncology Congress; September 28 to October 2, 2012; Vienna, Austria.
9. M.R. Smith, C. Sweeney, and D.E. Rathkopf Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): results from a phase II nonrandomized expansion cohort (NRE) [abstract 4513] J Clin Oncol 30 Suppl 2012
10. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. US Food and Drug Administration Web site. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed October 28, 2013.
11. US Food and Drug Administration. Guidance for industry. Qualification process for drug development tools. 2010. US Food and Drug Administration Web site. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf. Accessed October 28, 2013.
12. E. Basch Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels Value Health 15 2012 401 403
13. E. Basch, A.M. Trentacosti, and L.B. Burke Pain palliation measurement in cancer clinical trials: the FDA perspective Cancer 120 2014 761 767
14. C.J. Logothetis, E. Basch, and A. Molina Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial Lancet Oncol 13 2012 1210 1217
15. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
16. J.S. De Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
17. M. Brundage, J. Blazeby, and D. Revicki Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards Qual Life Res 22 2013 1161 1175
18. E. Basch, A.P. Abernethy, and C.D. Mullins Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology J Clin Oncol 30 2012 4249 4255
19. D. Patrick, C. Acquadro, B. Teschendorf, M.P. Emery, M. Caron, and B. Arnould PCN119 patient-reported outcomes (PROs) in antineoplastic product approvals in Europe and in the USA Value Health 15 2012 A431
20. J.T. Farrar, J.P. Young Jr., L. LaMoreaux, J.L. Werth, and R.M. Poole Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale Pain 94 2001 149 158
21. R.H. Dworkin, D.C. Turk, and K.W. Wyrwich Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations J Pain 9 2008 105 121
22. M.R. Smith, C. Sweeney, and P.G. Corn Cabozantinib in chemotherapy-pretreated metastatic castrationresistant prostate cancer: results of a phase II nonrandomized expansion study J Clin Oncol 32 2014 3391 3399
23. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
24. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
25. C.S. Cleeland, and K.M. Ryan Pain assessment: global use of the Brief Pain Inventory Ann Acad Med Singapore 23 1994 129 138
26. C.S. Cleeland, T.R. Mendoza, and X.S. Wang Assessing symptom distress in cancer: the M. D. Anderson Symptom Inventory Cancer 89 2000 1634 1646
27. Swarm R, Pickar Abernethy A, Anghelescu DL, et al. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: adult cancer pain (version 2.2011). National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
28. R.C. Serlin, T.R. Mendoza, and Y. Nakamura When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function Pain 61 1995 277 284
29. H.M. Nguyen, N. Ruppender, and X. Zhang Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling PLoS One 8 2013 e78881
30. J. Dai, H. Zhang, and A. Karatsinides Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions Clin Cancer Res 20 2014 617 630
31. M.J. Fisch, J.W. Lee, and M. Weiss Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer J Clin Oncol 30 2012 1980 1988
32. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
33. T.M. Atkinson, T.R. Mendoza, and L. Sit The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations Pain Med 11 2010 337 346
34. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764